Kodu・Aktsiate loetelu・AtriCure Inc

AtriCure Inc

Avatud

SektorTervishoid

39.02 1.51

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

38.35

Max

39.19

Põhinäitajad
By Trading Economics
Sissetulek	8.8M 9M
Müük	12M 154M
P/E Sektori keskmine	177.952 64.641
Aktsiakasum	0.18
Kasumimarginaal	5.83
Töötajad	1,350
EBITDA	-3.8M 3.2M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+22.13% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	28. okt 2026

Turustatistika
By TradingEconomics
Turukapital	132M 1.9B
Eelmine avamishind	37.51
Eelmine sulgemishind	39.02

Uudiste sentiment

By Acuity

34%

66%

104 / 340 Pingereas Healthcare

AtriCure Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. aug 2026, 20:06 UTC

AtriCure Inc. shares are higher during Monday's session, regaining ground after an earlier pullback. Broader market trends support positive investor sentiment.

31. juuli 2026, 20:03 UTC

News

AtriCure shares are lower amid significant insider selling, including a $233,280 sale by Chief Scientific Officer Vinayak Doraiswamy and options exercised by Board Member Sven Wehrwein.

30. juuli 2026, 18:56 UTC

AtriCure Inc's shares are lower today, impacted by declines in the Health Care Equipment sub-sector. No specific company news was identified for the movement.

29. juuli 2026, 20:03 UTC

News

AtriCure Inc shares reached a 52-week high of $43.18 following better-than-expected quarterly earnings, despite a pullback earlier in the session.

28. juuli 2026, 19:21 UTC

AtriCure Inc's shares are higher today amid stronger gains in U.S. and European indices, with no specific company news identified for the movement.

27. juuli 2026, 20:02 UTC

News

AtriCure Inc shares are higher as the company prepares for two investor conferences and highlights CEO Michael Carrel's leadership appointment.

24. juuli 2026, 21:41 UTC

AtriCure Inc. shares traded roughly flat in after-market hours. The stock has performed well recently, positioned near the upper end of its monthly range.

23. juuli 2026, 21:51 UTC

News

AtriCure reported strong Q2 results and raised EPS guidance but shares fell in after-market trading, marking the sixth consecutive session of declines.

22. juuli 2026, 19:56 UTC

AtriCure Inc shares are trading lower, reaching a session low just before 15:30 ET, despite remaining above the 20-day moving average.

21. juuli 2026, 19:16 UTC

AtriCure Inc shares are trading lower today, continuing a trend of declines over the past three sessions, despite gains in the Nasdaq 100 Index.

20. juuli 2026, 19:51 UTC

AtriCure Inc continues higher today, maintaining strength since Friday's close, despite a recent pullback earlier in the session.

Võrdlus sarnastega

Hinnamuutus

AtriCure Inc Prognoos

Hinnasiht

By TipRanks

22.13% tõus

12 kuu keskmine prognoos

Keskmine 47.29 USD 22.13%

Kõrge 55 USD

Madal 36 USD

Põhineb 8 Wall Streeti analüütiku instrumendi AtriCure Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi AtriCure Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

104 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest AtriCure Inc

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.